Back to top

LACOG 0720 – SMART-KEY

  /    /  LACOG 0720 – SMART-KEY

SMART-KEY: A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers

Type of Study: Clinical Trial

Sponsor / Support: LACOG

Primary Objectives: To evaluate laryngectomy-free survival of a treatment regimen consisting of induction chemo-immunotherapy, followed by radioimmunotherapy, followed by consolidation immunotherapy.

Design: This a prospective, single-arm, multi-institutional, open label, phase 2 trial evaluating the effects of induction chemo-immunotherapy, followed by radioimmunotherapy, followed by consolidation immunotherapy in patients with locally advanced squamous cell carcinoma of the larynx who are candidates for organ preservation.

Sample Size: 39 patients

Principal Investigator: William William

Countries LATAM: Brazil

Clinicaltrials.gov Identifier: NCT04943445

The study is open to patients participation in the following research sites:

Liga Norte Riograndense Contra o Câncer / Natal / RN / Brazil

Fundação Pio XII - Hospital de Câncer de Barretos / Barretos / SP / Brazil

BP – A Beneficência Portuguesa de São Paulo / São Paulo / SP / Brazil

CRIO - Centro Regional Integrado de Oncologia / Fortaleza / CE / Brazil